Myocardial Infarction (MI)NCT07741721
Optimal Timing of Staged Complete Revascularization in STEMI With Multivessel Disease (OPTION-STEMI2)
A study testing In-hospital staged complete revascularization and Out-of-hospital staged complete revascularization in people with Myocardial Infarction (MI), run by Chonnam National University Hospital at 30 sites in South Korea.
Trial summary
This prospective, multicenter, open-label, superiority trial will enroll patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease. Following successful percutaneous coronary intervention (PCI) of the infarct-related artery (IRA), patients who meet the eligibility criteria will be… Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- Myocardial Infarction (MI)
- What is being tested?
- In-hospital staged complete revascularization and Out-of-hospital staged complete revascularization
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,252 participants
- Where
- 30 sitesSouth Korea
- Study dates
- 21 Aug 2026to 31 Jul 2035
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥19 years
- ST-segment elevation myocardial infarction (STEMI): ST-segment elevation ≥ 0.1 mV in at least two contiguous leads, or New-onset left bundle branch block (LBBB)
- Primary PCI within 12 h after symptom development
- At least 1 non-infarct related artery (non-IRA) with diameter ≥ 2.5 mm and 50% stenosis by visual estimation
Who cannot join
- Cardiogenic shock at initial presentation or after infarct-related artery (IRA) treatment
- Thrombolysis in myocardial infarction flow at non-IRA ≤ 2
- Severe procedural complications during primary percutaneous coronary intervention that, in the judgement of the operator, preclude study enrollment
- Non-IRA lesion unsuitable for percutaneous coronary intervention (PCI) treatment that, in the judgement of the operator, preclude study enrollment
- Chronic total occlusion in a non-IRA
- History of anaphylaxis to contrast agent
Show all 12Show fewer
- Pregnancy and lactation
- Life expectancy < 1 year
- Severe valvular heart disease
- History of coronary artery bypass grafting (CABG) or planned CABG
- Fibrinolysis therapy prior to admission
- Severe asthma
Trial locations and contacts
30 sites in 1 country. Contact the study team or a site near you to ask about taking part.
30 sites in 1 country
South Korea30 sites, 30 recruiting
- Not yet recruiting
Bucheon Sejong Hospital
Bucheon-si
- Not yet recruiting
Gyeongsang National University Changwon Hospital
Changwon
- Not yet recruiting
Samsung Changwon Medical Center
Changwon
- Not yet recruiting
Soon Chun Hyang University Hospital Cheonan
Cheonan
- Not yet recruiting
Chungbuk National University Hospital
Cheongju-si
- Not yet recruiting
Kangwon National University Hospital
Chuncheon
- Not yet recruiting
Daegu Catholic University Medical Center
Daegu
- Not yet recruiting
Keimyung University Dongsan Hospital
Daegu
- Not yet recruiting
Kyungpook National University Hospital
Daegu
- Not yet recruiting
Yeongnam University Medical Center
Daegu
- Not yet recruiting
Chungnam National University Hospital
Daejeon
- Recruiting
Chonnam National University Hospital
Gwangju
- Not yet recruiting
Chosun University Hospital
Gwangju
- Not yet recruiting
Gwangju Veterans Hospital
Gwangju
- Not yet recruiting
Kwangju Christian Hospital
Gwangju
- Not yet recruiting
Chung-Ang University Gwangmyeong Hospital
Gwangmyeong
- Not yet recruiting
Jeju National University Hospital
Jeju City
- Not yet recruiting
Jeonbuk National University Hospital
Jeonju
- Not yet recruiting
Presbyterian Medical Center
Jeonju
- Not yet recruiting
Gyeongsang National University Hospital
Jinju
- Not yet recruiting
Inje University Busan Paik Hospital
Pusan
- Not yet recruiting
Inje University Haeundae Paik Hospital
Pusan
- Not yet recruiting
Kosin University Gospel Hospital
Pusan
- Not yet recruiting
Pusan National University Hospital
Pusan
- Not yet recruiting
Koera University Guro Hospital
Seoul
- Not yet recruiting
Korea University Anam Hospital
Seoul
- Not yet recruiting
Yonsei University Health System, Gangnam Severance Hospital
Seoul
- Not yet recruiting
St. Carollo General Hospital
Suncheon
- Not yet recruiting
Ajou University Hospital
Suwon
- Not yet recruiting
Pusan National University Yangsan Hospital
Yangsan
About this study
Official title: OPtimal TIming of Staged Complete RevascularizatiON in ST-Segment Elevation Myocardial Infarction With Multivessel Disease: The OPTION-STEMI2 Trial
This prospective, multicenter, open-label, superiority trial will enroll patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease. Following successful percutaneous coronary intervention (PCI) of the infarct-related artery (IRA), patients who meet the eligibility criteria will be randomized in a 1:1 ratio to either in-hospital staged complete revascularization with PCI of non-IRA lesions performed on a separate day during hospitalization, at least 48 hours after PCI of the IRA, or out-of-hospital staged complete revascularization with PCI of non-IRA lesions performed after discharge between 15 and 45 days of randomization. In both groups, non-IRA lesions with 50-69% stenosis will be evaluated using FFR.
Read the detailed description
- Study Objectives: To determine the optimal timing of staged complete revascularization guided by fractional flow reserve (FFR) (in-hospital staged complete revascularization vs. out-of-hospital staged complete revascularization) in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease.
- Study Background: Approximately half of patients with STEMI have multivessel coronary artery disease, which is associated with worse clinical outcomes than single vessel disease. Complete revascularization has become the standard interventional strategy for the management of these patients. Regarding the timing of complete revascularization, two recent randomized clinical trials demonstrated that immediate complete revascularization was non-inferior to staged complete revascularization in patients with STEMI. In this context, the 2023 European guidelines give a class IA recommendation for complete revascularization, either during the index procedure or within 45 days. The 2025 American guidelines recommend immediate complete revascularization with a class IIb recommendation for hemodynamically stable patients with STEMI and low-complex anatomy. However, in these trials, planned staged revascularization in the staged group was performed after hospital discharge rather than during the index admission. In those previous trials, the timing of staged revascularization was median 15 days (IQR 4-28) in the BIOVASC trial and median 37 days (IQR 30-43) in the MULTISTARS AMI trial, and most clinical events in the staged group (mainly due to unplanned revascularization and myocardial infarction) had occurred during the early phase after the index procedure with the possibility of progression of a non-infarct related artery (non-IRA) lesion before the staged procedure. Greater inflammatory status during the acute phase of myocardial infarction might be associated with these findings. The OPTION-STEMI trial, which compared immediate and staged complete revascularization during index hospitalization, failed to demonstrate non-inferiority for the primary endpoint at 1 year (13% in the immediate complete revascularization group and 11% in the staged complete revascularization group; hazard ratio 1.24; 95% confidence interval 0.86-1.79; P for non-inferiority = 0.024). Therefore, it remains unclear whether the treatment effect differs between in-hospital and out-of-hospital staged complete revascularization in patients with STEMI and multivessel disease. The investigators designed a prospective, open-label, multicenter, superiority trial to evaluate the efficacy and safety of in-hospital staged complete revascularization compared with out-of-hospital staged complete revascularization in patients with STEMI and multivessel disease. Non-IRA lesions with 50-69% stenosis will be assessed using FFR, whereas those with ≥ 70% stenosis will undergo revascularization without FFR assessment. The investigators hypothesize that in-hospital staged complete revascularization may mitigate the risk of early progression of non-IRA lesions, compared with out-of-hospital staged complete revascularization, without increasing the procedural risk associated with immediate complete revascularization.
- Study Hypothesis: In-hospital staged complete revascularization would reduce the risk of the primary composite endpoint (a composite of all-cause death, non-fatal myocardial infarction, or all unplanned revascularization) at 12 months compared with out-of-hospital staged complete revascularization in patients with STEMI and multivessel disease.
- Conditions
- Myocardial Infarction (MI)
- Being tested
- In-hospital staged complete revascularization, Out-of-hospital staged complete revascularization
- Keywords
- ST-segment myocardial infarction, Multivessel coronary artery disease, Complete revascularization, Timing
- Medical subject headings
- Myocardial Infarction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
In-hospital staged complete revascularizationProcedure or surgery
PCI of non-IRA lesions will be performed on a separate day during the index hospitalization, at least 48 hours after PCI of the IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion will be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
Out-of-hospital staged complete revascularizationProcedure or surgery
PCI of non-IRA lesions will be performed after discharge and between 15 and 45 days of randomization. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion will be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
| Study group | Role | What they receive |
|---|---|---|
| In-hospital staged complete revascularization | Experimental | In the in-hospital staged complete revascularization group, PCI of non-IRA lesions will be performed on a separate day during the index hospitalization, at least 48 hours after PCI of the IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion will be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized. Receives: Procedure: In-hospital staged complete revascularization |
| Out-of-hospital staged complete revascularization | Active comparator | In the out-of-hospital staged complete revascularization group, PCI of non-IRA lesions will be performed after discharge and between 15 and 45 days of randomization. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion will be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized. Receives: Procedure: Out-of-hospital staged complete revascularization |
What is being measured
The primary outcome is the main question the study is designed to answer.
Composite of all-cause death, nonfatal myocardial infarction, or all unplanned revascularization
Composite of all-cause death, nonfatal myocardial infarction, or all unplanned
Measured: At 12 months after randomization
Secondary outcomes (17)
Composite of all-cause death, nonfatal myocardial infarction, or all unplanned revascularization
Composite of all-cause death, nonfatal myocardial infarction, or all unplanned
Measured: At 1, 6, 24, 36, 48, and 60 months after randomization
All-cause death
All-cause death
Measured: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Nonfatal myocardial infarction
Nonfatal myocardial infarction
Measured: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
All unplanned revascularization
All unplanned revascularization
Measured: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Cardiac death
Cardiac death
Measured: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Non-cardiac death
Non-cardiac death
Measured: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Nonfatal spontaneous myocardial infarction
Nonfatal spontaneous myocardial infarction
Measured: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Nonfatal procedure-related myocardial infarction
Nonfatal procedure-related myocardial infarction
Measured: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Target-lesion revascularization
Target-lesion revascularization
Measured: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Target-vessel revascularization
Target-vessel revascularization
Measured: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Non-target vessel revascularization
Non-target vessel revascularization
Measured: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Hospitalization for unstable angina
Hospitalization for unstable angina
Measured: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Hospitalization for heart failure
Hospitalization for heart failure
Measured: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Stent thrombosis
Stent thrombosis
Measured: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Stroke
Stroke
Measured: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Major bleeding
Major bleeding
Measured: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Contrast-induced nephropathy
Contrast-induced nephropathy
Measured: At hospital discharge (up to 30 days)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Aug 2026
- Study start21 Aug 2026
- Primary completion31 Jul 2031 (estimated)
- Study completion31 Jul 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myocardial Infarction (MI)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 1,252 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chonnam National University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Min Chul Kim, MD, Chonnam National University Hospital
- Investigators
- Youngkeun Ahn, MD, PhD, Principal investigator, Chonnam National University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07741721
- Sponsor's protocol ID
- CNUH-2026-258
- Status last verified
- Oct 2026
- First submitted
- 26 Jul 2026
- Last updated
- 23 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- OPtimal TIming of Staged Complete RevascularizatiON in ST-Segment Elevation Myocardial Infarction With Multivessel Disease: The OPTION-STEMI2 Trial
- ClinicalTrials.gov ID
- NCT07741721
- Acronym / sponsor ID
- CNUH-2026-258
- Conditions
- Myocardial Infarction (MI)
- Keywords
- ST-segment myocardial infarction, Multivessel coronary artery disease, Complete revascularization, Timing
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 1,252 participants (estimated)
- Lead sponsor
- Chonnam National University HospitalUniversity, hospital or other
- Study start
- 21 Aug 2026 (actual)
- Primary completion
- 31 Jul 2031 (estimated)
- Study completion
- 31 Jul 2035 (estimated)
- First posted
- 3 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective, multicenter, open-label, superiority trial will enroll patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease. Following successful percutaneous coronary intervention (PCI) of the infarct-related artery (IRA), patients who meet the eligibility criteria will be randomized in a 1:1 ratio to either in-hospital staged complete revascularization with PCI of non-IRA lesions performed on a separate day during hospitalization, at least 48 hours after PCI of the IRA, or out-of-hospital staged complete revascularization with PCI of non-IRA lesions performed after discharge between 15 and 45 days of randomization. In both groups, non-IRA lesions with 50-69% stenosis will be evaluated using FFR.
Detailed description
- Study Objectives: To determine the optimal timing of staged complete revascularization guided by fractional flow reserve (FFR) (in-hospital staged complete revascularization vs. out-of-hospital staged complete revascularization) in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease.
- Study Background: Approximately half of patients with STEMI have multivessel coronary artery disease, which is associated with worse clinical outcomes than single vessel disease. Complete revascularization has become the standard interventional strategy for the management of these patients. Regarding the timing of complete revascularization, two recent randomized clinical trials demonstrated that immediate complete revascularization was non-inferior to staged complete revascularization in patients with STEMI. In this context, the 2023 European guidelines give a class IA recommendation for complete revascularization, either during the index procedure or within 45 days. The 2025 American guidelines recommend immediate complete revascularization with a class IIb recommendation for hemodynamically stable patients with STEMI and low-complex anatomy. However, in these trials, planned staged revascularization in the staged group was performed after hospital discharge rather than during the index admission. In those previous trials, the timing of staged revascularization was median 15 days (IQR 4-28) in the BIOVASC trial and median 37 days (IQR 30-43) in the MULTISTARS AMI trial, and most clinical events in the staged group (mainly due to unplanned revascularization and myocardial infarction) had occurred during the early phase after the index procedure with the possibility of progression of a non-infarct related artery (non-IRA) lesion before the staged procedure. Greater inflammatory status during the acute phase of myocardial infarction might be associated with these findings. The OPTION-STEMI trial, which compared immediate and staged complete revascularization during index hospitalization, failed to demonstrate non-inferiority for the primary endpoint at 1 year (13% in the immediate complete revascularization group and 11% in the staged complete revascularization group; hazard ratio 1.24; 95% confidence interval 0.86-1.79; P for non-inferiority = 0.024). Therefore, it remains unclear whether the treatment effect differs between in-hospital and out-of-hospital staged complete revascularization in patients with STEMI and multivessel disease. The investigators designed a prospective, open-label, multicenter, superiority trial to evaluate the efficacy and safety of in-hospital staged complete revascularization compared with out-of-hospital staged complete revascularization in patients with STEMI and multivessel disease. Non-IRA lesions with 50-69% stenosis will be assessed using FFR, whereas those with ≥ 70% stenosis will undergo revascularization without FFR assessment. The investigators hypothesize that in-hospital staged complete revascularization may mitigate the risk of early progression of non-IRA lesions, compared with out-of-hospital staged complete revascularization, without increasing the procedural risk associated with immediate complete revascularization.
- Study Hypothesis: In-hospital staged complete revascularization would reduce the risk of the primary composite endpoint (a composite of all-cause death, non-fatal myocardial infarction, or all unplanned revascularization) at 12 months compared with out-of-hospital staged complete revascularization in patients with STEMI and multivessel disease.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| In-hospital staged complete revascularization | Experimental | Procedure: In-hospital staged complete revascularizationIn the in-hospital staged complete revascularization group, PCI of non-IRA lesions will be performed on a separate day during the index hospitalization, at least 48 hours after PCI of the IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion will be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized. |
| Out-of-hospital staged complete revascularization | Active comparator | Procedure: Out-of-hospital staged complete revascularizationIn the out-of-hospital staged complete revascularization group, PCI of non-IRA lesions will be performed after discharge and between 15 and 45 days of randomization. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion will be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized. |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age ≥19 years
- ST-segment elevation myocardial infarction (STEMI): ST-segment elevation ≥ 0.1 mV in at least two contiguous leads, or New-onset left bundle branch block (LBBB)
- Primary PCI within 12 h after symptom development
- At least 1 non-infarct related artery (non-IRA) with diameter ≥ 2.5 mm and 50% stenosis by visual estimation
Key exclusion criteria (12 listed)
- Cardiogenic shock at initial presentation or after infarct-related artery (IRA) treatment
- Thrombolysis in myocardial infarction flow at non-IRA ≤ 2
- Severe procedural complications during primary percutaneous coronary intervention that, in the judgement of the operator, preclude study enrollment
- Non-IRA lesion unsuitable for percutaneous coronary intervention (PCI) treatment that, in the judgement of the operator, preclude study enrollment
- Chronic total occlusion in a non-IRA
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| In-hospital staged complete revascularizationPCI of non-IRA lesions will be performed on a separate day during the index hospitalization, at least 48 hours after PCI of the IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion will be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized. | Procedure or surgery | In-hospital staged complete revascularization |
| Out-of-hospital staged complete revascularizationPCI of non-IRA lesions will be performed after discharge and between 15 and 45 days of randomization. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion will be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized. | Procedure or surgery | Out-of-hospital staged complete revascularization |
Primary outcome
Composite of all-cause death, nonfatal myocardial infarction, or all unplanned revascularization
Time frame: At 12 months after randomization
Composite of all-cause death, nonfatal myocardial infarction, or all unplanned
17 secondary outcomes
Composite of all-cause death, nonfatal myocardial infarction, or all unplanned revascularization
Time frame: At 1, 6, 24, 36, 48, and 60 months after randomization
All-cause death
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Nonfatal myocardial infarction
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
All unplanned revascularization
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Cardiac death
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Non-cardiac death
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Nonfatal spontaneous myocardial infarction
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Nonfatal procedure-related myocardial infarction
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Target-lesion revascularization
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Target-vessel revascularization
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Non-target vessel revascularization
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Hospitalization for unstable angina
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Hospitalization for heart failure
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Stent thrombosis
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Stroke
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Major bleeding
Time frame: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Contrast-induced nephropathy
Time frame: At hospital discharge (up to 30 days)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Myocardial Infarction (MI)
RecruitingPhase 2
Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction
Myocardial Infarction, Reperfusion Injury
Recruiting
ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY
Myocardial Infarction (MI), Sudden Cardiac Death Due to Cardiac Arrhythmia
RecruitingObservational study
Breisgau PHENO-HEART MI
Myocardial Infarction, STEMI
Not yet recruiting
Pilot Study to Determine the Optimal Protocol for Preoperative Transcutaneous Vagal Neurostimulation
Atrial Fibrillation (AF), Cerebral Vascular Accident (CVA)
Active, not recruiting
Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
Acute Myocardial Infarction, Coronary Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Youngkeun Ahn, MD, PhD principal investigator
Chonnam National University Hospital
30 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing In-hospital staged complete revascularization and Out-of-hospital staged complete revascularization in people with Myocardial Infarction (MI), run by Chonnam National University Hospital at 30 sites in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 30 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Min Chul Kim, MD, PhD (82-10-4606-2643, kmc3242@hanmail.net), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Composite of all-cause death, nonfatal myocardial infarction, or all unplanned revascularization (time frame: At 12 months after randomization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Oct 2026.